跳至主要内容
临床试验/NL-OMON45252
NL-OMON45252
已完成
不适用

Assessment of a novel strategy to attenuate muscle mass loss during 2 weeks of bed rest - Bed rest & Blood flow restriction

niversiteit Maastricht0 个研究点目标入组 19 人待定

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
未指定
发起方
niversiteit Maastricht
入组人数
19
状态
已完成
最后更新
2年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
2年前
研究类型
Interventional

研究者

入排标准

入选标准

  • Healthy males
  • Age between 18 and 35 y
  • BMI between 18\.5 and 30 kg/m2

排除标准

  • \-Type 2 Diabetes Mellitus
  • \-Any back/leg/knee/neck/postural complaints \*
  • \-Any history or family history of thrombosis\*
  • \-All co\-morbidities interacting with mobility and muscle metabolism of the lower limbs \*(e.g. arthritis, spasticity/rigidity, all neurological disorders and paralysis)
  • \-Myocardial infarction within the last 3 years
  • \-Use of certain anti\-coagulants (use of thrombocyte aggregation inhibitors such as Ascal, \*acetylsalicylic acid, aspirin and carbasalaatcalcium is permitted. Use of other thrombocyte aggregation inhibitors will be discussed with the responsible physician) \*
  • \-Performing regular resistance training (3\+ times per week, carrying out progressive training) in the previous 6 months
  • \-Hypertension (according to WHO criteria) and/or cardiovascular disease
  • \-A history of deep vein thrombosis (DVT) in the leg
  • \-Having donated blood in the 3 months prior to the study

结局指标

主要结局

未指定

相似试验